Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Warsaw - Delayed Quote PLN

Pharmena S.A. (PHR.WA)

4.3100
+0.0100
+(0.23%)
At close: April 28 at 4:36:56 PM GMT+2
Loading Chart for PHR.WA
  • Previous Close 4.3000
  • Open 4.3100
  • Bid 4.2800 x --
  • Ask 4.3100 x --
  • Day's Range 4.2800 - 4.3100
  • 52 Week Range 3.5200 - 6.6800
  • Volume 4,316
  • Avg. Volume 2,505
  • Market Cap (intraday) 48.339M
  • Beta (5Y Monthly) 1.17
  • PE Ratio (TTM) 143.67
  • EPS (TTM) 0.0300
  • Earnings Date May 26, 2025 - May 30, 2025
  • Forward Dividend & Yield 0.85 (19.54%)
  • Ex-Dividend Date Apr 9, 2024
  • 1y Target Est --

Pharmena S.A., a biotechnology company, manufactures and sells active ingredients in various areas of medicines in Poland and internationally. The company offers dermatological cosmetics, including face, hair, and body care products, as well as dietary supplement. It offers its products under the Menavitin, Dermena, Allerco, and Thermi names. Pharmena S.A. was founded in 2002 and is based in Lódz, Poland.

www.pharmena.eu

15

Full Time Employees

December 31

Fiscal Year Ends

Recent News: PHR.WA

View More

Performance Overview: PHR.WA

Trailing total returns as of 4/28/2025, which may include dividends or other distributions. Benchmark is MSCI WORLD (^990100-USD-STRD) .

YTD Return

PHR.WA
12.53%
MSCI WORLD (^990100-USD-STRD)
2.37%

1-Year Return

PHR.WA
33.69%
MSCI WORLD (^990100-USD-STRD)
8.86%

3-Year Return

PHR.WA
16.78%
MSCI WORLD (^990100-USD-STRD)
29.32%

5-Year Return

PHR.WA
67.51%
MSCI WORLD (^990100-USD-STRD)
79.51%

Compare To: PHR.WA

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: PHR.WA

View More

Valuation Measures

Annual
As of 4/25/2025
  • Market Cap

    48.00M

  • Enterprise Value

    37.36M

  • Trailing P/E

    143.33

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    4.86

  • Price/Book (mrq)

    4.08

  • Enterprise Value/Revenue

    3.78

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -10.94%

  • Return on Equity (ttm)

    -9.79%

  • Revenue (ttm)

    308k

  • Net Income Avi to Common (ttm)

    -1.68M

  • Diluted EPS (ttm)

    0.0300

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    10.8M

  • Total Debt/Equity (mrq)

    1.32%

  • Levered Free Cash Flow (ttm)

    -2.28M

Research Analysis: PHR.WA

View More

Company Insights: PHR.WA

Research Reports: PHR.WA

View More

People Also Watch